FDA Approval: 1L Amivantamab Plus Chemotherapy for EGFR Exon 20 NSCLC
Podcast | English | XX Min
Image For Activity Cover
Cost
$0.00
Credit
No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCLC with an EGFR exon 20 insertion based on the phase III PAPILLON trial. These data were first shared at ESMO 2023 in Madrid with a simultaneous publication in the New England Journal of Medicine. 

Podcast Hosts:
  • Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA 

Podcast Guests: 

  • Michael Boyer, MD, Professor and Kam Ling Barbara Lo Chair in Lung and Thoracic Cancer at the University of Sydney, and CEO of Chris O'Brien Lifehouse, Sydney, Australia
  • Angel Qin, Clinical Assistant Professor adn Co-Chair of the Thoracic Clinical Research Team, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA
Powered By